Introduction
To assess the efficacy of endotracheal administration of adrenaline (epinephrine) in humans.
Methods
• Prospective randomized trial involving 34 anesthetized patients (5 women, 29 men) receiving an implantable cardio-verter defibrillator.
• After intubation, when mean arterial pressure (MAP) fell below 80 mmHg (after adequate fluid loading), IV adrenaline was injected via central line, at a dose of 1 µg/kg, with dose escalation to achieve the required MAP.
• Once the IV dose was established, the next time they were hypotensive, 100 times the IV dose was administered diluted in 10 ml of saline and administered slowly over 5 seconds into the airways, followed by 10 forced ventilations.
• There were two subgroups: one group received adrenaline directly into the ET (n = 17), and the other received adrenaline via a bronchial catheter wedged into a bronchus (laced under radiological guidance) (n = 17).
• The patients' clinical characteristics apparently did not differ between groups (data not shown).
• Mean dose of adrenaline ± SD = 1.3 ± 0.6 mg (range, 0.7 to 3 µg)
• Plasma catecholamine samples were collected from the second lumen of the central intravenous line immediately before adrenaline administration; 0.5, 2, 3, and 5 min after IV administration; and 0.5, 2, 3, 5, 10, and 20 min after ET administration.
Results
Airway administration of adrenaline significantly increased plasma adrenaline levels more than 200-fold, from 0.26 ± 0.21 nmol/l (range, 0.05 to 0.71 nmol/l) to 57.9 ± 56.8 nmol/l (range, 8.2 to 205.8 nmol/l) (P = 0.0015). MAP increased by almost 100% (P < 0.001), and heart rate increased from 64.0 ± 12.6 beats/min (range, 40 to 100 beats/min) to a maximum of 79.7 ± 20.5 beats/min (range, 50-140 beats/min). A delayed response was seen when adrenaline was administered through the airways. Mean time to first response in MAP of >10 mmHg, via the IV route, was 25.1 ± 15.1 seconds (SD 3.6-79.2) and via the ET route 64.0 ± 68.5 seconds (SD 8.4-279.6), P < 0.001. Mean time to reach the peak effect on MAP in seconds via IV route was 82.3 ± 31.0 (SD 11-131) and via the ET route was 219.8 ± 136.2 (SD 62-528), P < 0.001. There was no statistical difference between the two airway subgroups. ET administration of adrenaline appears as effective as IV; however, a time lag was seen and peripheral bronchial administration of adrenaline through a catheter (which is cumbersome and time-consuming) seems unnecessary. 
